The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Preventing and Managing Toxicities of High-Dose Methotrexate
Open accessAbstract
High-dose methotrexate (HDMTX), defined as a dose higher than 500 mg/m2, is used to treat a range of adult and childhood cancers. Although HDMTX is safely administered to most patients, it can cause significant toxicity, including acute kidney injury (AKI) in 2%–12% of patients. Nephrotoxicity results from crystallization of methotrexate in the renal tubular lumen, leading to tubular toxicity. AKI and other toxicities of high-dose methotrexate can lead to significant morbidity, treatment delays, and diminished renal function. Risk factors for methotrexate-associated toxicity include a history of renal dysfunction, volume depletion, acidic urine, and drug interactions. Renal toxicity leads to impaired methotrexate clearance and prolonged exposure to toxic concentrations, which further worsen renal function and exacerbate nonrenal adverse events, including myelosuppression, mucositis, dermatologic toxicity, and hepatotoxicity. Serum creatinine, urine output, and serum methotrexate concentration are monitored to assess renal clearance, with concurrent hydration, urinary alkalinization, and leucovorin rescue to prevent and mitigate AKI and subsequent toxicity. When delayed methotrexate excretion or AKI occurs despite preventive strategies, increased hydration, high-dose leucovorin, and glucarpidase are usually sufficient to allow renal recovery without the need for dialysis. Prompt recognition and effective treatment of AKI and associated toxicities mitigate further toxicity, facilitate renal recovery, and permit patients to receive other chemotherapy or resume HDMTX therapy when additional courses are indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sonis, S. T. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1318 · Cited by 1,361
Watson, W. A., Litovitz, T. L., Rodgers, G. C., Klein-Schwartz, W., Reid, N., Youniss, J., Flanagan, A., & Wruk, K. M. (2005) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2005.05.001 · Cited by 1,148
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., Chesney, M., Clark-Snow, R. A., Flaherty, A. M., Freundlich, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4614 · Cited by 1,059
Understanding and Managing Methotrexate Nephrotoxicity
Widemann, B. C., & Adamson, P. C. (2006) · The Oncologist · doi:10.1634/theoncologist.11-6-694 · Cited by 730
Cronstein, B. N., Naime, D., & Ostad, E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116884 · Cited by 679
Interventions for treating oral mucositis for patients with cancer receiving treatment
Clarkson, J. E., Worthington, H. V., Furness, S., McCabe, M., Khalid, T., & Meyer, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001973.pub4 · Cited by 674
Methotrexate for Rheumatoid Arthritis
Kremer, J. M., Alarcón, G. S., Lightfoot, R. W., Willkens, R. F., Furst, D. E., Williams, H. J., Dent, P. B., & Weinblatt, M. E. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370304 · Cited by 607
Long-term survival in primary CNS lymphoma.
Abrey, L. E., DeAngelis, L. M., & Yahalom, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.859 · Cited by 577
Sonis, S. T. (1998) · Oral Oncology · doi:10.1016/s1368-8375(97)00053-5 · Cited by 565
Batchelor, T., Carson, K., O’Neill, A., Grossman, S. A., Alavi, J., New, P., Hochberg, F., & Priet, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.036 · Cited by 546
Pui, C.-H., Sandlund, J. T., Pei, D., Campana, D., Rivera, G. K., Ribeiro, R. C., Rubnitz, J. E., Razzouk, B. I., Howard, S. C., Hudson, M. M., et al. (2004) · Blood · doi:10.1182/blood-2004-04-1616 · Cited by 463
Self-citationFerrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., Alvegard, T. A., Picci, P., Capanna, R., Bernini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5785 · Cited by 435
Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia
Bhojwani, D., Sabin, N. D., Pei, D., Yang, J. J., Khan, R. B., Panetta, J. C., Krull, K. R., Inaba, H., Rubnitz, J. E., Metzger, M. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0808 · Cited by 400
Self-citationGoorin, A. M., Schwartzentruber, D. J., Devidas, M., Gebhardt, M. C., Ayala, A. G., Harris, M. B., Helman, L. J., Grier, H. E., & Link, M. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.165 · Cited by 395
Souhami, R. L., Craft, A. W., Van der Eijken, J. W., Nooij, M., Spooner, D., Bramwell, V. H., Wierzbicki, R., Malcolm, A. J., Kirkpatrick, A., Uscinska, B. M., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02307-6 · Cited by 383
Drug Prescribing in Renal Failure: Dosing Guidelines for Adults.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-502_4 · Cited by 360
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function
KINTZEL, P. (1995) · Cancer Treatment Reviews · doi:10.1016/0305-7372(95)90010-1 · Cited by 357
Treviño, L. R., Shimasaki, N., Yang, W., Panetta, J. C., Cheng, C., Pei, D., Chan, D., Sparreboom, A., Giacomini, K. M., Pui, C.-H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4156 · Cited by 349
Self-citationFuchs, N., Bielack, S. S., Epler, D., Bieling, P., Delling, G., Körholz, D., Graf, N., Heise, U., Jürgens, H., Kotz, R., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008391103132 · Cited by 343
Howard, S. C. (2004) · JAMA · doi:10.1001/jama.291.20.2471 · Cited by 313
Self-citationA biological approach to mucositis.
Sonis, S. T. (2004) · PubMed · Cited by 299
Mahoney, D. H., Shuster, J. J., Nitschke, R., Lauer, S. J., Steuber, C. P., Winick, N., & Camitta, B. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1712 · Cited by 290
Perazella, M. A., & Moeckel, G. W. (2010) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2010.09.005 · Cited by 287
Interventions for preventing oral mucositis for patients with cancer receiving treatment
Worthington, H. V., Clarkson, J. E., Bryan, G., Furness, S., Glenny, A.-M., Littlewood, A., McCabe, M. G., Meyer, S., Khalid, T., & Riley, P. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000978.pub5 · Cited by 262
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
Ramsey, L. B., Bruun, G. H., Yang, W., Treviño, L. R., Vattathil, S., Scheet, P., Cheng, C., Rosner, G. L., Giacomini, K. M., Fan, Y., et al. (2012) · Genome Research · doi:10.1101/gr.129668.111 · Cited by 261
Self-citationJacobs, S. A., Stoller, R. G., Chabner, B. A., & Johns, D. G. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108308 · Cited by 257
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
Thomas, D. A., O'Brien, S., Cortes, J., Giles, F. J., Faderl, S., Verstovsek, S., Ferrajoli, A., Koller, C., Beran, M., Pierce, S., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4428 · Cited by 255
High-dose methotrexate: a critical reappraisal.
Ackland, S. P., & Schilsky, R. L. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.12.2017 · Cited by 254
Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
Relling, M. V., Fairclough, D., Ayers, D., Crom, W. R., Rodman, J. H., Pui, C. H., & Evans, W. E. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1667 · Cited by 215
Self-citationGenome-wide study of methotrexate clearance replicates SLCO1B1
Ramsey, L. B., Panetta, J. C., Smith, C., Yang, W., Fan, Y., Winick, N. J., Martin, P. L., Cheng, C., Devidas, M., Pui, C.-H., et al. (2013) · Blood · doi:10.1182/blood-2012-08-452839 · Cited by 208
Self-citationChen, S. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070653 · Cited by 206
Intensified and Shortened Cyclical Chemotherapy for Adult Acute Lymphoblastic Leukemia
Linker, C., Damon, L., Ries, C., & Navarro, W. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.116 · Cited by 199
Chemotherapy-associated renal dysfunction
Sahni, V., Choudhury, D., & Ahmed, Z. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.97 · Cited by 183
Neoadjuvant chemotherapy for osteosarcoma of the extremity
Bacci, G., Briccoli, A., Ferrari, S., Longhi, A., Mercuri, M., Capanna, R., Donati, D., Lari, S., Forni, C., & DePaolis, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00229-5 · Cited by 174
The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides.
Pinedo, H. M., Zaharko, D. S., Bull, J. M., & Chabner, B. A. (1976) · PubMed · Cited by 164
Aminophylline for methotrexate-induced neurotoxicity
Bernini, J. C., Fort, D. W., Griener, J. C., Kane, B. J., Chappell, W. B., Kamen, B. A., & Kamen, B. A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90464-6 · Cited by 163
Abelson, H. T., Fosburg, M. T., Beardsley, G. P., et al. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.3.208 · Cited by 149
Rubnitz, J. E., Relling, M. V., Harrison, P., Sandlund, J. T., Ribeiro, R., Rivera, G. K., Thompson, S., Evans, W., & Pui, C.-H. (1998) · Leukemia · doi:10.1038/sj.leu.2401098 · Cited by 128
Self-citationLIVER BIOPSIES FROM PSORIATICS RELATED TO METHOTREXATE THERAPY
Nyfors, A. (1977) · Acta Pathologica Microbiologica Scandinavica Section A Pathology · doi:10.1111/j.1699-0463.1977.tb03882.x · Cited by 116
Pitman, S. W., & Frei, E. (1977) · PubMed · Cited by 115
May, J. E., Carson, K. R., Butler, S. K., Liu, W., Bartlett, N. L., & Wagner‐Johnston, N. D. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.840780 · Cited by 107
Schwartz, S., Borner, K., Müller, K., et al. (2007) · The Oncologist · doi:10.1634/theoncologist.12-11-1299 · Cited by 95
Melatonin attenuates methotrexate‐induced oxidative stress and renal damage in rats
Abraham, P., Kolli, V. K., & Rabi, S. (2010) · Cell Biochemistry and Function · doi:10.1002/cbf.1676 · Cited by 89
Lindsay, K., Fraser, A., Layton, A., Goodfield, M. J. D., Gruss, H. J., & Gough, A. (2008) · Lara D. Veeken · doi:10.1093/rheumatology/kep023 · Cited by 84
Hill, F. G. H., Richards, S. M., Gibson, B. E. S., Hann, I. M., Lilleyman, J., Kinsey, S. E., Mitchell, C., Harrison, C. J., & Eden, O. B. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04738.x · Cited by 79
Drug prescribing in renal failure: Dosing guidelines for adults
Matzke, G. R. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70132-0 · Cited by 78
Hamada, K., Kakigawa, N., Sekine, S., Shitara, Y., & Horie, T. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2238-2 · Cited by 68
Increased Susceptibility to Methotrexate-Induced Toxicity in Nonalcoholic Steatohepatitis
Hardwick, R. N., Clarke, J., Lake, A. D., Canet, M. J., Anumol, T., Street, S. M., Merrell, M. D., Goedken, M. J., Snyder, S. A., & Cherrington, N. J. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu156 · Cited by 63
Glomerular Function Time Trends in Long-Term Survivors of Childhood Cancer: A Longitudinal Study
Mulder, R. L., Knijnenburg, S. L., Geskus, R. B., van Dalen, E. C., van der Pal, H. J. H., Koning, C. C. E., Bouts, A. H. M., Caron, H. N., & Kremer, L. C. M. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0036 · Cited by 61
de Miguel, D., García‐Suárez, J., Martín, Y. P., et al. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn503 · Cited by 47
Ibrahim, M. A., El‐Sheikh, A. A. K., Khalaf, H. M., et al. (2014) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2014.884135 · Cited by 46
Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis
Schmidt, E., Thoennissen, N. H., Rudat, A., Bieker, R., Schliemann, C., Mesters, R. M., Zühlsdorf, M., Müller‐Tidow, C., & Berdel, W. E. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn179 · Cited by 38
Protective Effect of Amifostine on High-Dose Methotrexate-Induced Small Intestinal Mucositis in Mice
Chen, C., Li, T. X., Zhang, M., Sun, Q., Zhang, X., Li, X., Cao, X., Liu, Q., Li, X., & Li, H. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2826-3 · Cited by 29
Fijlstra, M., Tissing, W. J. E., Stellaard, F., Verkade, H. J., & Rings, E. H. H. M. (2012) · Clinical Nutrition · doi:10.1016/j.clnu.2012.10.002 · Cited by 29
In vitro and in vivo protein binding of methotrexate assessed by microdialysis.
Maia, M. B., Saivin, S., Chatelut, É., Malmary, M.-F., & Houin, G. (1996) · PubMed · Cited by 27
The Weaned Pig as a Model for Doxorubicin-Induced Mucositis
Martin, J. C., Howard, S. C., Pillai, A. B., Vogel, P., Naren, A. P., Davis, S., Ringwald-Smith, K., Buddington, K. K., & Buddington, R. K. (2014) · Chemotherapy · doi:10.1159/000365725 · Cited by 21
Self-citationWANG, J., & Li, G. (2014) · Oncology Letters · doi:10.3892/ol.2014.2773 · Cited by 20
Cited by
Histidine catabolism is a major determinant of methotrexate sensitivity
Kanarek, N., Keys, H. R., Cantor, J. R., Lewis, C. A., Chan, S. H., Kunchok, T., Abu-Remaileh, M., Freinkman, E., Schweitzer, L. D., & Sabatini, D. M. (2018) · Nature · doi:10.1038/s41586-018-0316-7 · Cited by 321
Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
Chrysostomou, D., Roberts, L. A., Marchesi, J. R., & Kinross, J. M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.10.018 · Cited by 283
Hecker-Nolting, S., Langer, T., Blattmann, C., Kager, L., & Bielack, S. S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s287908 · Cited by 10
Metadata
- Authors
- Howard, S. C., McCormick, J., Pui, C.-H., Buddington, R. K., & Harvey, R. D.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-08-05
- Volume
- 21
- Issue
- 12
- Pages
- 1471-1482
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2493103431
- Cited by
- 929
- References
- 57
- FWCI
- 32.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.